메지온

140410KOSDAQ자연과학 및 공학 연구개발업

49.8 / 100

Reference Date: 2026-07-24

Financial Score15.0 / 40

News Sentiment17.8 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is low with sound financial health but Revenue is on a declining trend. Declined 11.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Meizon is a pharmaceutical company established in 2002, focusing on global new drug development for various diseases, including erectile dysfunction and single-ventricle syndrome treatments. Although it submitted a New Drug Application (NDA) to the FDA for a single-ventricle syndrome treatment in 2021, the application was temporarily withdrawn following a request for additional clinical trials, and the company is now proceeding with the additional trial process.

Number of Employees

18people

Average Salary

63.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

—Industry Average 2.523.5Point

ROE

-110.44Industry Average -32.093.5Point

3.4x industry avg (excellent)

Debt Ratio

7.31Industry Average 7.314.0Point

In line with industry avg

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼40.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼8.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -58.6% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 2Neutral 1Negative 1Average Sentiment Score 71.2

Positive
"이제는 상업화만 남았다"…메지온 폰탄 치료제, 글로벌 빅파마 러브.....
메지온의 유데나필 치료제가 간질환 개선 효과를 입증하며 글로벌 빅파마들의 관심을 끌어 긍정적인 시장 반응을 예상한다.
Negative
LG家 장녀 부부 '미공개 정보 이용' 2심…자금 집행 직원 증인 채택
LG 가족의 미공개 정보 이용 혐의로 인한 재판 진행이 메지온 주가에 부정적 영향을 미칠 것으로 예상됩니다.
Positive
“환자 1200만명, 치료제는 단 하나”…메지온, FDA 2상 직행 속...
메지온의 FDA 2상 직행 소식으로 희귀질환 치료제 개발에 대한 긍정적 전망이 형성되었다.

Detailed Momentum

52-week position1.0Point

Near 52w low (12%, downtrend)

Current 52,800Won52-week high 172,70052-week low 36,450

1-month return1.0Point

1m -11.26% (falling)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-21
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-14
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-30